Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies

In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra(®)) has been developed and has replaced Vivaglobin(®) (SCIG 16%). An o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Immunopathol Pharmacol
Main Authors: Canessa, Clementina, Iacopelli, Jessica, Pecoraro, Antonio, Spadaro, Giuseppe, Matucci, Andrea, Milito, Cinzia, Vultaggio, Alessandra, Agostini, Carlo, Cinetto, Francesco, Danieli, Maria Giovanna, Gambini, Simona, Marasco, Carolina, Trizzino, Antonino, Vacca, Angelo, De Mattia, Domenico, Martire, Baldassarre, Plebani, Alessandro, Di Gioacchino, Mario, Gatta, Alessia, Finocchi, Andrea, Licciardi, Francesco, Martino, Silvana, De Carli, Marco, Moschese, Viviana, Azzari, Chiara
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2016
Assuntos:
Letters to the Editor
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5806788/
https://ncbi.nlm.nih.gov/pubmed/27927705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0394632016681577
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares